Fecal volatile organic compounds for early detection of colorectal cancer: where are we now?
- PMID: 30554400
- PMCID: PMC11810243
- DOI: 10.1007/s00432-018-2821-3
Fecal volatile organic compounds for early detection of colorectal cancer: where are we now?
Abstract
Introduction: The fecal volatolome, which is composed of fecal volatile organic compounds (VOCs), seems to hold potential as non-invasive biomarker for the detection of colorectal cancer (CRC) and its precursor lesions advanced adenomas (AA). The potential of the fecal volatolome has been subject of various studies using either chemical analytical or pattern-recognition techniques. The available literature on the potential of the fecal volatolome as CRC and AA biomarker was reviewed.
Methods: A systematic literature search was conducted in PubMed, Embase, the Cochrane Library, Google Scholar and ResearchGate using the following keywords: Colorectal Cancer, Advanced Adenoma, Volatile Organic Compound, Metabolome, Gas Chromatrography-Mass Spectrometry, Selected-Ion Flow-Tube Mass Spectrometry, eNose, and Fecal Biomarkers.
Results: Eighty-eight titles or abstracts were identified from the search, of which 11 papers describing the potential of the fecal volatolome for CRC detection were selected. In these studies, different techniques were used for the headspace analyses of fecal VOCs, limiting the possibility to compare outcomes. Increased levels of amino acids and short chain fatty acids, and decreased levels of bile acids and polyol alcohols in the gas phase of feces were observed repeatedly. All selected papers reported high diagnostic value for the detection of both CRC and AA based on fecal VOCs.
Conclusion: Based on the included studies, fecal VOC analyses seem promising for future screening of CRC and AA, with potentially improved test performances allowing for earlier detection of AA and CRC and consequently earlier initiation of treatment, possibly reducing morbidity and mortality rates next to lower rates of (unnecessary) colonoscopies.
Keywords: Advanced adenoma; Biomarker; Colorectal carcinoma; Screening; Volatile organic compounds.
Conflict of interest statement
S. Bosch declares that she has no conflict of interest. D. J. Berkhout declares that he has no conflict of interest. I. Ben Larbi declares that she has no conflict of interest. Tim G. de Meij served in the advisory board of Danone. Nanne K. de Boer has served as a speaker for AbbVie and MDS. He has served as consultant and principal investigator for TEVA Pharma BV and Takeda. He has received a (unrestricted) grant from Dr. Falk and Takeda.
Similar articles
-
Urinary volatile organic compounds for colorectal cancer screening: A systematic review and meta-analysis.Eur J Cancer. 2023 Jun;186:69-82. doi: 10.1016/j.ejca.2023.03.002. Epub 2023 Mar 6. Eur J Cancer. 2023. PMID: 37030079
-
Study protocol: the 'Endoscope CRC' cohort, a prospective biobank study on the development and evaluation of diagnostic and prognostic biomarker profiles for colorectal cancer and premalignant lesions.BMJ Open. 2024 Nov 14;14(11):e083229. doi: 10.1136/bmjopen-2023-083229. BMJ Open. 2024. PMID: 39542477 Free PMC article.
-
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD009276. doi: 10.1002/14651858.CD009276.pub2. Cochrane Database Syst Rev. 2022. PMID: 35665911 Free PMC article.
-
Fecal volatile organic compounds for colorectal cancer detection: A systematic review and meta-analysis.Comput Biol Med. 2025 Sep;195:110561. doi: 10.1016/j.compbiomed.2025.110561. Epub 2025 Jun 25. Comput Biol Med. 2025. PMID: 40570763 Review.
-
The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.BMC Cancer. 2022 Dec 12;22(1):1299. doi: 10.1186/s12885-022-10372-2. BMC Cancer. 2022. PMID: 36503495 Free PMC article.
Cited by
-
Simultaneous Assessment of Urinary and Fecal Volatile Organic Compound Analysis in De Novo Pediatric IBD.Sensors (Basel). 2019 Oct 16;19(20):4496. doi: 10.3390/s19204496. Sensors (Basel). 2019. PMID: 31623289 Free PMC article.
-
Use of Omics Technologies for the Detection of Colorectal Cancer Biomarkers.Cancers (Basel). 2022 Feb 6;14(3):817. doi: 10.3390/cancers14030817. Cancers (Basel). 2022. PMID: 35159084 Free PMC article. Review.
-
The Influence of Mechanical Bowel Preparation on Volatile Organic Compounds for the Detection of Gastrointestinal Disease-A Systematic Review.Sensors (Basel). 2023 Jan 26;23(3):1377. doi: 10.3390/s23031377. Sensors (Basel). 2023. PMID: 36772415 Free PMC article.
-
Faecal Volatile Organic Compounds to Detect Colorectal Neoplasia in Lynch Syndrome-A Prospective Longitudinal Multicentre Study.Aliment Pharmacol Ther. 2025 Jan;61(1):145-158. doi: 10.1111/apt.18328. Epub 2024 Oct 18. Aliment Pharmacol Ther. 2025. PMID: 39422092 Free PMC article.
-
Bile-volatile organic compounds in the diagnostics of pancreatic cancer and biliary obstruction: A prospective proof-of-concept study.Front Oncol. 2022 Nov 21;12:918539. doi: 10.3389/fonc.2022.918539. eCollection 2022. Front Oncol. 2022. PMID: 36479080 Free PMC article.
References
-
- Arasaradnam RP, Covington JA, Harmston C, Nwokolo CU (2014) Review article: next generation diagnostic modalities in gastroenterology–gas phase volatile compound biomarker detection. Aliment Pharmacol Ther 39:780–789. 10.1111/apt.12657 - PubMed
-
- Atkin WS, Morson BC, Cuzick J (1992) Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 326:658–662. 10.1056/NEJM199203053261002 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical